Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14

Ironwood announced Praliciguat phase IIa study data

Ironwood Pharmaceuticals presented additional data from an exploratory Phase IIa study of praliciguat in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida. Praliciguat is an oral, once-daily soluble guanylate cyclase stimulator that is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction. Building on previously announced top-line data from the Phase IIa randomized, placebo-controlled, 14-day study, which showed that treatment with praliciguat led to reductions in blood pressure, fasting plasma glucose, cholesterol levels and triglycerides in patients on a stable regimen of medicines to manage their disease, the newly reported findings also suggested that praliciguat improved insulin sensitivity. Insulin resistance is a hallmark of diabetes and often linked to hypertension. In addition, the data suggested that praliciguat decreased levels of apolipoprotein B, a key lipid parameter that - when elevated - is associated with increased cardiac events. The effect of praliciguat on ApoB in this Phase IIa study was shown within the context of broader lipid effects, including a reduction in total cholesterol and low-density lipoprotein cholesterol, the component of total cholesterol associated with long-term cardiovascular risk. The study was not designed or powered to assess efficacy, but the data yielded clear and consistent trends indicating a positive effect of praliciguat on blood pressure, metabolic parameters and endothelial function biomarkers. These improvements were seen in patients who were taking a stable regimen of therapies to manage their disease; all participating patients were taking at least one medication to manage their hypertension and at least one medication to manage their diabetes, and a majority were also taking additional medications to manage their cholesterol and serum lipid levels. The study also confirmed a pharmacokinetic profile of praliciguat supporting once-daily dosing and suggested broad distribution to relevant tissues, offering the potential to maximize anti-inflammatory, anti-fibrotic and metabolic effects. Praliciguat was generally well-tolerated. Nausea was the only adverse event present in the praliciguat group at a greater incidence rate than placebo. There was a single serious AE, an upper gastrointestinal hemorrhage in a participant with erosive esophagitis receiving praliciguat. Across all five clinical studies of praliciguat to date, praliciguat was found not to impair platelet function or blood clotting, either on its own or when co-administered with aspirin. No other serious bleeding episodes have been observed. All other AEs in this Phase IIa study were characterized as mild.

  • 25

    Jun

IRWD Ironwood
$19.35

0.74 (3.98%)

05/09/18
MSCO
05/09/18
DOWNGRADE
MSCO
Underweight
Ironwood downgraded to Underweight from Equal Weight at Morgan Stanley
05/09/18
05/09/18
DOWNGRADE
Target $13

Underweight
Ironwood downgraded to Underweight on Linzess growth concerns at Morgan Stanley
As previously reported, Morgan Stanley analyst David Lebowitz downgraded Ironwood to Underweight from Equal Weight as he believes management's target of Linzess U.S. sales exceeding $1B by 2020 could be a challenge given the recent deceleration in volume growth. Also, while the company has multiple mid-to-late stage pipeline products, Lebowitz is not yet comfortable enough with them to incorporate them into his valuation, he tells investors. He lowered his price target on Ironwood shares to $13 from $15.
05/09/18
05/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Crocs (CROX) downgraded to Hold from Buy at Stifel with analyst Jim Duffy saying he believes the stock has "adequately" re-rated to discount fiscal 2019 earnings power. 2. Monster Beverage (MNST) downgraded to Neutral from Overweight at JPMorgan with analyst Andrea Teixeira saying she sees a "difficult road ahead" for the company following its first quarter results. 3. Adient (ADNT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying that recent management commentary appears to have taken the potential for strategic action involving the underperforming metals business off the table. 4. Ironwood (IRWD) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lebowitz saying he believes management's target of Linzess U.S. sales exceeding $1B by 2020 could be a challenge given the recent deceleration in volume growth. 5. Papa John's (PZZA) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying he is concerned Papa John's may not have a recovery in comps in the near-term and recommends investors wait for a significant pullback and or evidence same-store-sales being to recover in the coming quarters before becoming constructive on shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/18
WELS
05/30/18
NO CHANGE
Target $22
WELS
Outperform
Ironwood price target raised to $22 from $18 at Wells Fargo
Wells Fargo analyst David Maris raised his price target on Ironwood to $22 and kept his Outperform rating, saying he is updating his model following the company's Q1 earnings as well as its announcement of separating its soluble guanylate cyclase business. While the analyst also lowers his FY18 EPS view to (67c) from (38c) to reflect the separation, he adds that future commercial/GI-focused IRWD earnings should no longer be depressed by R&D spending on the sGC assets.

TODAY'S FREE FLY STORIES

BLK

BlackRock

$404.72

-22.68 (-5.31%)

15:21
10/16/18
10/16
15:21
10/16/18
15:21
Recommendations
BlackRock analyst commentary  »

BlackRock weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

VRSK

Verisk Analytics

$115.81

2.5 (2.21%)

15:20
10/16/18
10/16
15:20
10/16/18
15:20
Hot Stocks
Geomni forms strategic alliance with Skyline Software Systems »

Geomni, a Verisk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

OSTK

Overstock.com

$26.96

0.18 (0.67%)

15:19
10/16/18
10/16
15:19
10/16/18
15:19
Hot Stocks
Overstock announces completion of issuance of preferred tZERO security tokens »

tZERO, a portfolio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$72.25

1.39 (1.96%)

15:19
10/16/18
10/16
15:19
10/16/18
15:19
Options
CSX options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

FCB

FCB Financial

$43.96

-0.69 (-1.55%)

15:17
10/16/18
10/16
15:17
10/16/18
15:17
Hot Stocks
FCB does not see material adverse portfolio impact from Hurricane Michael »

FCB Financial reports it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/16/18
10/16
15:17
10/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/16/18
10/16
15:16
10/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
10/16/18
10/16
15:05
10/16/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MAXR

Maxar Technologies

$30.30

0.89 (3.03%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Hot Stocks
Maxar's MDA ships final spacecraft in preparation for RADARSAT mission »

MDA, a Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$144.76

3.64 (2.58%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Options
IBM options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

BA

Boeing

$367.17

8.36 (2.33%)

15:02
10/16/18
10/16
15:02
10/16/18
15:02
Hot Stocks
Boeing sees air cargo traffic doubling in 20 years »

Boeing projects air cargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

CLDR

Cloudera

$15.68

0.44 (2.89%)

15:01
10/16/18
10/16
15:01
10/16/18
15:01
Hot Stocks
Cloudera announces strategic alliance with NEC »

Cloudera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MNKD

MannKind

$1.90

0.24 (14.46%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Hot Stocks
FDA sends warning letter to MannKind over Affrezza marketing »

In a warning letter sent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.93

1.44 (3.10%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Options
Call spread in Crown Holdings in front of earnings »

Call spread in Crown…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

, JPM

JPMorgan

$108.59

2.25 (2.12%)

14:55
10/16/18
10/16
14:55
10/16/18
14:55
Recommendations
On Deck Capital, JPMorgan analyst commentary  »

Janney Montgomery Scott…

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

JPM

JPMorgan

$108.59

2.25 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 06

    Nov

  • 26

    Feb

OSTK

Overstock.com

$27.11

0.33 (1.23%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Hot Stocks
Overstock.com says Customer Day 'strongest' non-Holiday sale in company history »

Overstock.com reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$60.29

1.36 (2.31%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Options
DowDuPont draws call buyers »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$341.60

8.49 (2.55%)

14:49
10/16/18
10/16
14:49
10/16/18
14:49
Options
Netflix options imply 14.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

14:45
10/16/18
10/16
14:45
10/16/18
14:45
General news
Canada Manufacturing Preview »

Canada Manufacturing…

H

Hyatt

$72.79

1.08 (1.51%)

14:42
10/16/18
10/16
14:42
10/16/18
14:42
Recommendations
Hyatt analyst commentary  »

Hyatt to-be-acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ALLY

Ally Financial

$25.87

-0.22 (-0.84%)

14:40
10/16/18
10/16
14:40
10/16/18
14:40
Options
Ally Financial attracts put buying as shares see relative weakness »

Ally Financial attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CDNS

Cadence Design

$40.13

0.74 (1.88%)

14:34
10/16/18
10/16
14:34
10/16/18
14:34
Hot Stocks
Cadence Design says Verification Suite enabled for HPC server environments »

Cadence Design Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

EEM

iShares MSCI Emerging Markets ETF

$40.79

0.95 (2.38%)

14:30
10/16/18
10/16
14:30
10/16/18
14:30
Options
Aggressive call spread opened in iShares Emerging Markets Fund »

Aggressive call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$36.25

3.81 (11.74%)

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Conference/Events
Financial Stability Oversight Council to hold a meeting »

The Council will provide…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.